Phase
Condition
Myasthenia Gravis (Chronic Weakness)
Muscular Dystrophy
Treatment
Placebo
NIDO-361
Clinical Study ID
Ages 18-70 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Ambulatory male
Documented SBMA diagnosis confirmed by DNA genetic testing
Able to complete six-minute walk test (6MWT)
Exclusion
Exclusion Criteria:
Clinically significant cardiovascular, endocrine, hepatic, renal, pulmonary,gastrointestinal, neurologic, immunologic, malignant, metabolic, psychiatric, orother condition that, in the opinion of the Investigator, precludes theparticipant's safe participation in the study or would interfere with the studyassessments
Inability to undergo MRI (mild sedation may be allowed)
Study Design
Connect with a study center
Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center
Copenhagen,
DenmarkSite Not Available
Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center
Copenhagen 2618425,
DenmarkSite Not Available
IRCCS Istituto Neurologico Carlo Besta
Milan 6951411,
ItalySite Not Available
IRCCS Istituto Neurologico Carlo Besta
Milano,
ItalySite Not Available
Azienda Ospedale Università di Padova
Padova,
ItalySite Not Available
Azienda Ospedale Università di Padova
Padua 3171728,
ItalySite Not Available
Kyungpook National University Chilgok Hospital
Daegu,
Korea, Republic ofSite Not Available
Kyungpook National University Chilgok Hospital
Daegu 1835329,
South KoreaSite Not Available
University of College London Hospital (UCLH)
London,
United KingdomSite Not Available
University of College London Hospital (UCLH)
London 2643743,
United KingdomSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.